[{"bbox": [90, 98, 367, 131], "category": "Page-header", "text": "Q-Line Biotech Limited"}, {"bbox": [90, 164, 1557, 834], "category": "Table", "text": "<table><thead><tr><th></th><th>31-03-2025</th><th>31-03-2024</th><th>31-03-2023</th></tr></thead><tbody><tr><td>(A) Capital Commitment</td><td></td><td></td><td></td></tr><tr><td>Estimated amount of contract remaining to be executed on capital account & not provided for (Capital Advance)</td><td></td><td></td><td></td></tr><tr><td>Purchase of Immovable Properties</td><td>-</td><td>579.53</td><td>888.98</td></tr><tr><td><strong>Total (A)</strong></td><td><strong>-</strong></td><td><strong>579.53</strong></td><td><strong>888.98</strong></td></tr><tr><td>(B) Contingent liability in respect of-</td><td></td><td></td><td></td></tr><tr><td>Guarantees given on Behalf of the Company</td><td>714.82</td><td>415.15</td><td>398.60</td></tr><tr><td>Income Tax Demand for the AY 2020-21</td><td>15.09</td><td>13.41</td><td>13.41</td></tr><tr><td>Traces Defaults</td><td>-</td><td>3.97</td><td>0.05</td></tr><tr><td>GST Demand</td><td>139.66</td><td></td><td></td></tr><tr><td><strong>Total (B)</strong></td><td><strong>869.57</strong></td><td><strong>432.53</strong></td><td><strong>412.06</strong></td></tr><tr><td>(C) Corporate Guarantee (on behalf of POCT Science House Private Limited)</td><td>1,060.00</td><td>1,060.00</td><td>1,060.00</td></tr><tr><td><strong>Total (C)</strong></td><td><strong>1,060.00</strong></td><td><strong>1,060.00</strong></td><td><strong>1,060.00</strong></td></tr><tr><td><strong>Total (A+B+C)</strong></td><td><strong>1,929.57</strong></td><td><strong>2,072.06</strong></td><td><strong>2,361.03</strong></td></tr></tbody></table>"}, {"bbox": [90, 866, 1559, 932], "category": "Text", "text": "For further details, please refer to Annexure AA – Contingent Liabilities & Capital Commitment of the chapter titled “Financial Information of the Company” on page 232 and 232 of this Draft Red Herring Prospectus."}, {"bbox": [90, 961, 800, 993], "category": "Section-header", "text": "## K. SUMMARY OF RELATED PARTY TRANSACTIONS"}, {"bbox": [90, 1026, 1559, 1091], "category": "Text", "text": "Following is the summary of the related party transactions entered by the Company (based on Consolidated Restated Financial Statements) for the financial year ended on March 31, 2025:"}, {"bbox": [90, 1121, 503, 1155], "category": "Text", "text": "List of Related Parties as per AS – 18"}, {"bbox": [90, 1182, 1557, 2149], "category": "Table", "text": "<table><thead><tr><th>Particulars</th><th>Names of related parties</th><th>Nature of Relationship</th></tr></thead><tbody><tr><td rowspan=\"14\">Directors and Key Management Personnel (KMP)</td><td>Saurabh Garg</td><td>Promoter, Managing Director and Chairman</td></tr><tr><td>Amita Garg</td><td>Promoters and Non-Executive Director</td></tr><tr><td>Ajay Kumar Mahanty</td><td>Whole-Time Director</td></tr><tr><td>Ayush Garg</td><td>Promoters & Non-Executive Director</td></tr><tr><td>Kuldeep Chowdhry</td><td>Whole-Time Director</td></tr><tr><td>Abhay Agarwal</td><td>Promoters & Non-Executive Director</td></tr><tr><td>Manisha Yadav</td><td>Directorship(removed w.e.f 18th April 2024)</td></tr><tr><td>Pravir Kumar</td><td>Independent Director (w.e.f. 08th May, 2025)</td></tr><tr><td>Rohit Nandan</td><td>Independent Director (w.e.f. 08th May, 2025)</td></tr><tr><td>Jai Prakash Singh</td><td>Independent Director (w.e.f. 01st August, 2025)</td></tr><tr><td>Abhishek Mishra</td><td>Independent Director (w.e.f. 08th May, 2025)</td></tr><tr><td>Prabhakara Subraya Yethadka</td><td>Whole-Time Director (w.e.f 08th May, 2025)</td></tr><tr><td>Meenal Gupta</td><td>CFO (w.e.f 25th July, 2025)</td></tr><tr><td>Akhand Pratap Singh</td><td>Company Secretary (w.e.f 25th July, 2025)</td></tr><tr><td rowspan=\"8\">Enterprises in which KMP/Relatives of KMP can exercise significant influence</td><td>POCT Science House Private Limited</td><td>Associates (Ceased w.e.f. 20th March, 2025)</td></tr><tr><td>Q Line Healthcare Private Limited</td><td>Common Directorship</td></tr><tr><td>Heidelco Medicore Private Limited</td><td>Subsidiary (Ceased w.e.f. 24.03.2025)</td></tr><tr><td>Q-Line Nutraceuticals Private Limited (effective from August 07, 2023)</td><td>Common Directorship</td></tr><tr><td>ASG Buildtech Private Limited</td><td>Subsidiary (w.e.f 07th March, 2025)</td></tr><tr><td>POCT Quality & Skill Development Private Limited</td><td>Subsidiary (w.e.f 07th March, 2025)</td></tr><tr><td>Mediquity Technologies Private Limited</td><td>Subsidiary (w.e.f 07th December, 2023)</td></tr><tr><td>Q-Line Innovations Private Limited (effective from 07th March, 2025)</td><td>Subsidiary (w.e.f 07th December, 2023)</td></tr></tbody></table>"}, {"bbox": [808, 2171, 839, 2200], "category": "Page-footer", "text": "23"}]